Virtu Financial LLC Purchases Shares of 6,176 Becton Dickinson and Co (BDX)

Virtu Financial LLC purchased a new stake in Becton Dickinson and Co (NYSE:BDX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 6,176 shares of the medical instruments supplier’s stock, valued at approximately $1,322,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Legacy Advisors LLC lifted its holdings in Becton Dickinson and by 7,000.0% in the 4th quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares during the last quarter. FTB Advisors Inc. lifted its holdings in Becton Dickinson and by 114.2% in the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in Becton Dickinson and in the 4th quarter worth approximately $136,000. Exane Derivatives lifted its holdings in Becton Dickinson and by 848.6% in the 4th quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 628 shares during the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in Becton Dickinson and in the 4th quarter worth approximately $160,000. 77.50% of the stock is owned by institutional investors and hedge funds.

Becton Dickinson and Co (NYSE:BDX) opened at $218.32 on Friday. Becton Dickinson and Co has a 1-year low of $175.66 and a 1-year high of $248.39. The company has a market capitalization of $58,227.23, a P/E ratio of 22.69, a PEG ratio of 1.56 and a beta of 1.12. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same period in the previous year, the company earned $2.33 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. equities research analysts anticipate that Becton Dickinson and Co will post 10.94 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be paid a $0.75 dividend. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. Becton Dickinson and’s payout ratio is 229.01%.

BDX has been the subject of several analyst reports. Royal Bank of Canada restated a “sector perform” rating and issued a $230.00 target price (up from $210.00) on shares of Becton Dickinson and in a report on Friday, November 3rd. Zacks Investment Research lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Deutsche Bank set a $260.00 target price on Becton Dickinson and and gave the stock a “buy” rating in a report on Friday, December 29th. KeyCorp initiated coverage on Becton Dickinson and in a report on Friday, January 5th. They issued an “overweight” rating and a $260.00 target price for the company. Finally, Stifel Nicolaus restated a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus target price of $237.27.

In related news, Director Timothy M. Ring sold 269,661 shares of the company’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the transaction, the director now directly owns 295,753 shares in the company, valued at $64,420,918.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.00% of the company’s stock.

WARNING: “Virtu Financial LLC Purchases Shares of 6,176 Becton Dickinson and Co (BDX)” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://stocknewstimes.com/2018/02/23/virtu-financial-llc-purchases-shares-of-6176-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply